Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) has issued an update.
Guangzhou Baiyunshan Pharmaceutical Holdings Company announced that all resolutions at its first Extraordinary General Meeting (EGM) of 2025 were approved by shareholders. The meeting, held on January 21, 2025, was attended by a significant portion of shareholders, reflecting strong engagement and support for the company’s strategic decisions. This approval signifies a positive outlook for the company’s future operations and reinforces its position in the pharmaceutical industry.
More about Guangzhou Baiyunshan Pharmaceutical Holdings Company
Guangzhou Baiyunshan Pharmaceutical Holdings Company is a joint stock company based in the People’s Republic of China, operating in the pharmaceutical industry. It primarily engages in the production and distribution of pharmaceutical products, focusing on both domestic and international markets.
YTD Price Performance: -2.40%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.66B
For an in-depth examination of 0874 stock, go to TipRanks’ Stock Analysis page.
